Table 2.
Treatment and disease parameters at inclusion and at 2 years
| Inclusion (n = 232) | 2 years (n = 207) a |
|
|---|---|---|
| Current treatment | ||
| DMARD (any), n (%) | 190 (82) | 171 (83) |
| MTX, n (%) | 123 (53) | 125 (60) |
| MTX dose (mg/week) | 10 (7.5–10.0) | 10 (7.5–17.5) |
| Other DMARDS, n (%) | 67 (29) | 43 (21) |
| Concurrent prednisolone, n (%) | 89 (38) | 62 (30) |
| Prednisolone dose (mg/day) | 7.5 (5.0–15.0) | 5 (2.5-6.0) |
| Disease parameters | ||
| RF-positive at inclusion, n (%) | 143 (62) | N/A |
| Anti-CCP antibody-positive at inclusion, n (%) | 115 (57) | N/A |
| Erosions present b, n (%) | 35 (15) | 67 (32) |
| COMP (units/L) | 11 (9–14) | N/R |
| DAS28 | 4.7 (3.6–5.7) | 3.5 (2.6–4.5) |
| Low disease activity c, n (%) | 39 (17) | 85 (41) |
| Moderate disease activity c, n (%) | 103 (45) | 93 (45) |
| High disease activity c, n (%) | 89 (39) | 27 (13) |
| HAQ | 0.75 (0.38–1.25) | 0.50 (0.00–1.00) |
| ESR (mm/h) | 21 (10–43) | 15 (8–26) |
| CRP (mg/l) | 9 (< 9–28) | < 9 (< 9–11) |
Median (IQR) given unless otherwise stated
DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; RF, rheumatoid factor; N/A, not applicable; Anti-CCP, anti-cyclic citrullinated peptide antibodies; COMP, cartilage oligomeric matrix protein; N/R, not reported; DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IQR, inter quartile range
For treatment and disease parameters at inclusion/two years, missing numbers were as follows: Anti-CCP = 31/-, Erosion present = 0/7, COMP = 30/-, DAS28 = 1/2, HAQ = 1/0, ESR = 0/2.
a Patients with a clinical follow-up at 2 years
b Determined by a radiologist as part of standard clinical practice
c DAS28-classifications: Low ≤ 3.2; Moderate > 3.2-≤5.1; High > 5.1